SCHEMBL4844173

SCHEMBL4844173

Cc1ccc(CCC(=N)N)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.53
CYP1A2 P05177 1/20 0.52
CYP2A6 P11509 1/20 0.52
TAAR1 Q96RJ0 1/20 0.52
WDR5 P61964 1/20 0.47
FFAR1 O14842 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
SLC5A1 P13866 1/20 0.43
SLC5A2 P31639 1/20 0.43
NPC1 O15118 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
NOS1 P29475 1/20 0.42
RAB9A P51151 1/20 0.42
HIF1A Q16665 1/20 0.42
IGF1R P08069 1/20 0.41
ALOX15 P16050 1/20 0.41
BLM P54132 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4718195 0.98 IDO1 (0.55) IDO1CYP1A2CYP2A6TAAR1WDR5
SCHEMBL8780954 0.89 NOS1 (0.50) IDO1TAAR1FFAR1L3MBTL1NPC1
SCHEMBL12401897 0.82 NOS1 (0.45) IDO1NPC1CYP3A4CYP2D6NOS1
SCHEMBL12376924 0.80 NOS1 (0.43) IDO1NPC1CYP3A4CYP2D6NOS1
SCHEMBL20756202 0.80 CYP1A2 (0.48) IDO1CYP1A2CYP2A6TAAR1FFAR1
SCHEMBL12401872 0.80 CYP3A4 (0.43) NPC1CYP3A4CYP2D6NOS1RAB9A
SCHEMBL364573 0.78 FFAR1 (0.55) IDO1CYP1A2CYP2A6TAAR1FFAR1
SCHEMBL4843038 0.78 IDO1 (0.53) IDO1TAAR1FFAR1SLC5A1SLC5A2
SCHEMBL4847288 0.78 IDO1 (0.58) IDO1TAAR1FFAR1PLAAT3PLAAT5
SCHEMBL4847256 0.78 IDO1 (0.58) IDO1TAAR1FFAR1SLC5A1SLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11179355-B2 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof SIGNATURE THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
EP-2509602-B1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS SENHWA BIOSCIENCES INC (TW) 2017-01-25 EP disclosed
US-7462620-B2 Pyrimidinone derivatives and their use in the treatment of atherosclerosis SMITHKLINE BEECHAM, PLC (GB) 2008-12-09 US disclosed
US-20060241126-A1 Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis ELLIOTT RICHARD L 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11179355-B2 Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof ACHE, COMT, CES2 IDO1 396/4885CYP1A2 53/4885CYP2A6 68/4885
US-20060241126-A1 Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis PLA2G7, PLA2G1B, PLA2G4B IDO1 647/4885CYP1A2 899/4885CYP2A6 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.